Search Results for "tyrosine kinase inhibitor (TKI)"

A TKI Update for Wet AMD

Carl D. Regillo, MD and R.V. Paul Chan, MD, MSc, MBA, FACS

What Evidence Makes EYP-1901 a Promising Treatment for Wet AMD and DME?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Treating DR with Axitinib

Neal S. Shah, MD

Patient Selection for EYP-1901

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Reinjection Criteria

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Wet AMD and DME Therapy in Development

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

TKIs: How Do They Work?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

How Can a Multi-MOA Approach Benefit the Management of Wet AMD?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

How May Tolerance for Subretinal Fluid Change Given Sustained-Release EYP-1901?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

EYP1901 Mechanism of Action

Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 2 of 3)

Jay Sridhar, MD; Maggie Runner, MD; and Veeral Sheth, MD, MBA

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 3 of 3)

Jay Sridhar, MD; Durga Borkar, MD, MMCi; and Christina Weng, MD, MBA

Retinal Fluid Fluctuation’s Impact on Long-Term Visual Acuity (Ep. 1 of 3)

Jay Sridhar, MD; Danny Mammo, MD; and David Sarraf, MD

View More